Heartsciences' myovista® wavecgtm selected to be used in irish heart screening evaluation

Southlake, tx, aug. 24, 2023 (globe newswire) -- heart test laboratories, inc.  d/b/a heartsciences (nasdaq: hscs; hscsw) (“heartsciences” or the “company”), an artificial intelligence (ai)-based medical technology company focused on transforming ecgs/ekgs to save lives through earlier detection of heart disease, today announces that its myovista® wavecgtm has been selected by panaceaflo ltd to be used in dublin, ireland in its heart screening evaluation study.
HSCS Ratings Summary
HSCS Quant Ranking